Evidence map›Paper›PMID 31416271›Full record

ArticleMolecules (Basel, Switzerland)2019

Design, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent β-Carbolines as Potential Anticancer Agents.

Xiaofei Chen, Liang Guo, Qin Ma, Wei Chen, Wenxi Fan, Jie Zhang

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Modern Strategies for Heterocycle Synthesis.Molecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaofei ChenSchool of Chemistry and Chemical Engineering, Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan, Shihezi University, Shihezi 832003, China.
Liang GuoSchool of Chemistry and Chemical Engineering, Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan, Shihezi University, Shihezi 832003, China.
Qin MaXinjiang Huashidan Pharmaceutical Research Co. Ltd., 175 He Nan East Road, Urumqi 830011, China.
Wei ChenXinjiang Huashidan Pharmaceutical Research Co. Ltd., 175 He Nan East Road, Urumqi 830011, China.
Wenxi FanXinjiang Huashidan Pharmaceutical Research Co. Ltd., 175 He Nan East Road, Urumqi 830011, China.
Jie ZhangSchool of Chemistry and Chemical Engineering, Key Laboratory for Green Processing of Chemical Engineering of Xinjiang Bingtuan, Shihezi University, Shihezi 832003, China. zhangjie-xj@163.com.

Funding

the Program for Changjiang Scholars and Innovative Research Team in University IRT15R46the Scientific Research Innovation Project in Shihezi University SHYL-YB201804the Xinjiang Science and Technology Major Project 2016A03005-1
6 · The paper itself

Abstract

Utilizing a pharmacophore hybridization approach, we have designed and synthesized a novel series of 28 new heterobivalent β-carbolines. The in vitro cytotoxic potential of each compound was evaluated against the five cancer cell lines (LLC, BGC-823, CT-26, Bel-7402, and MCF-7) of different origin-murine and human, with the aim of determining the potency and selectivity of the compounds. Compound

Indexed as

Drug DesignAngiogenesis InhibitorsAnimalsAntineoplastic AgentsCarbolinesCell Line, TumorCell SurvivalChemistry Techniques, SyntheticChick EmbryoDrug Screening Assays, AntitumorHumansHydrazonesInhibitory Concentration 50Molecular StructureNeovascularization, PathologicStructure-Activity RelationshipAngiogenesis InhibitorsAntineoplastic AgentsCarbolinesHydrazonesacylhydrazone groupantitumorasymmetric dimeric β-carbolinecytotoxicstructure–activity relationship

Identifiers

PMID31416271
PMCPMC6720801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.